By Deidre McPhillips and Amanda Sealy, CNN
Drug maker Pfizer said Friday that at the end of government contracts, likely early next year, its covid-19 vaccine will sell for between $110 and $130 depending on the dose.
This pricing style comes down to higher distribution prices and an expected shift from multi-dose vials to single-dose vials.
This is the “commercial list price,” but the company says it doesn’t anticipate most people will have to pay out of pocket. He also highlighted his patient assistance program, which is helping other uninsured people get vaccinated.
For now, Covid-19 vaccines can still be obtained for free. Pfizer says it anticipates that the price of the Covid-19 vaccine may come into play when vaccine distribution and reimbursement shift from government contracts to the classic fitness system, as early as the first quarter of 2023.
Research published through the Kaiser Family Foundation this week said that without more investments or protections, the commercialization of Covid-19 preventive measures and countermeasures would create barriers to vaccines, tests and therapies, especially for the uninsured and underinsured.
Two key changes will lead to commercialization: the end of the U. S. government’s declaration. UU. de a public fitness emergency and the depletion of supplies purchased by the federal government. Each replacement creates its own demanding situations and, taken together, “can increase demanding situations,” the research says. .
There have been no adjustments; The physical emergency declaration was renewed last week for another 90 days. But Congress has yet to act on the Biden administration’s request for billions more dollars to ensure a robust and available source of covid-19 countermeasures.
Much of the government’s request for increased investment for covid-19 is a “critical demand” for resources for the progression of new vaccines and remedies that can cope with long-term variants of the coronavirus, said Dawn O’Connell, undersecretary for preparedness. and response within the U. S. Department of Health and Human Services. U. S.
“It would get us out of the rise and fall of cases,” he said at a news conference Wednesday organized via KFF.
The purpose is to avoid a scenario like last winter, where there was a shortage of testing due to a lack of anticipation for the Delta variant, said Jen Kates, senior vice president and head of global fitness and HIV policy at KFF.
Another portion of the investment would be used for the uninsured and ensure universal access to Covid-19 countermeasures, O’Connell said.
According to KFF’s analysis, once the measures are commercialized, uninsured adults would lose out due to loose vaccines. But remedies and testing would face the “most acute” challenges, and cost-sharing would affect the percentage of prices that would be covered through insurance.
The transition to commercialization has been a component of the plan, O’Connell said. This is how other fitness issues are addressed in the United States.
“But the procedure is complex,” he said. Regardless of whether we got funding from Covid, we were going to have to make that transition at some point. Part of the Covid call makes this a little less bumpy.
El-CNN-Wire™
News Channel 3-12 is committed to providing a forum for civil and constructive conversation.
Please keep your comments respectful and relevant. You can view our Community Guidelines by clicking here
If you’d like to share a story idea, submit it here.
Terms of Use
Privacy policy
Community Principles
FCC Public Archive
EEO Public Record Report
FCC Applications
Don’t sell my information